An Open-label, Long-term Extension Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of TLL-018 in Patients With Rheumatoid Arthritis
Latest Information Update: 01 Apr 2025
At a glance
- Drugs TLL 018 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Hangzhou Highlightll Pharmaceutical
- 25 Mar 2025 New trial record